A phase 3, randomized, open-label, multi-country study to evaluate the immunogenicity, safety, reactogenicity and persistence of a single dose of the RSVPreF3 OA investigational vaccine and different revaccination schedules in adults aged 60 years and above

Ogawa Masayuki0 个研究点目标入组 1,650 人开始时间: 2021年1月25日最近更新: 2023年11月20日

适应症

试验速览

阶段: 3 期
状态: 进行中（未招募）
发起方
入组人数: 1,650

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 60age old 至 ot applicable（—）
性别: All

入选标准

•Male or female participants greater than or equal to 60 YOA at first vaccination, who live in the community (CD participants) or in a Long-term care facility (LTCF participants).
•- Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
•- Written or witnessed informed consent obtained from the participant prior to performance of any study specific procedure.
•- Participants who are medically stable in the opinion of the investigator at the time of first vaccination. Patients with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study if considered by the investigator as medically stable.

排除标准

•[Medical conditions]
•- Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history and physical examination.
•- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
•- Hypersensitivity to latex.
•- Serious or unstable chronic illness.
•- Recurrent or un-controlled neurological disorders or seizures. Participants with medically-controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol.
•- Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
•- Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
•- Any history of dementia or any medical condition that moderately or severely impairs cognition.
•[Prior/Concomitant therapy]
•- Use of any investigational or non-registered product other than the study vaccine during the period beginning 30 days before the first dose of study vaccine, or planned use during the study period.
•- Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before each dose and ending 30 days after each dose of study vaccine administration, with the exception of inactivated, split virion and subunit influenza vaccines which can be administered up to 14 days before or from 14 days after each study vaccination.
•- Previous vaccination with an RSV vaccine.
•- Administration of long-acting immune-modifying drugs or planned administration at any time during the study period.
•- Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the first dose of study vaccine or planned administration during the study period.
•- Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first vaccine dose or planned administration during the study period. For corticosteroids, this will mean prednisone 20 mg/day, or equivalent. Inhaled and topical steroids are allowed.
•[Prior/Concurrent clinical study experience]
•- Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product.
•[Other exclusions]
•- History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
•- Bedridden participants.
•- Planned move during the study period that will prohibit participation in the trial until the study end. This includes,
•- Planned move during the study period to another LTCF that will prohibit participation in the trial until study end.
•- Planned move from the community to a LTCF that will prohibit participation in the trial until study end.
•- Participation of any study personnel or their immediate dependants, family, or household members.

研究者

发起方

Ogawa Masayuki

相似试验

进行中（未招募）

1 期

EUCTR2019-004680-51-DEGlaxoSmithKline Biologicals SA1,653

招募中

1 期

Immunogenicity, safety, reactogenicity and persistence of an investigational respiratory syncytial virus (RSV) vaccine in adults aged 60 years and above.Respiratory Syncytial Virus Infections

CTIS2024-512291-34-00GlaxoSmithKline Biologicals1,650

招募中

3 期

Immunogenicity, safety, reactogenicity and persistence of an investigational respiratory syncytial virus (RSV) vaccine in adults aged 60 years and above.

2024-512291-34-00GlaxoSmithKline Biologicals738

招募中

1 期

An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adults 60 years of age and above who participated in RSV OA=ADJ-006 studyRespiratory Syncytial Virus InfectionsMedDRA version: 21.1Level: PTClassification code: 10035732Term: Pneumonia respiratory syncytial viral Class: 100000004862MedDRA version: 21.1Level: LLTClassification code: 10052200Term: Respiratory syncytial virus infection NOS Class: 10021881MedDRA version: 21.1Level: LLTClassification code: 10067384Term: Respiratory syncytial virus pneumonitis Class: 10021881MedDRA version: 21.1Level: LLTClassification code: 10035692Term: Pneumonia due to respiratory syncytial virus Class: 10021881MedDRA version: 21.1Level: PTClassification code: 10069811Term: Respiratory syncytial virus bronchitis Class: 100000004862MedDRA version: 21.1Level: PTClassification code: 10038718Term: Respiratory syncytial virus bronchiolitis Class: 100000004862MedDRA version: 21.1Level: PTClassification code: 10061603Term: Respiratory syncytial virus infection Class: 100000004862MedDRA version: 21.1Level: LLTClassification code: 10066741Term: Respiratory syncytial virus infection recurrent Class: 10021881

CTIS2023-509762-38-00GlaxoSmithKline Biologicals12,300

进行中（未招募）

1 期

A Phase 3 Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

EUCTR2017-001551-31-FRBeiGene, Ltd.467